LUPUS THERAPEUTIC MARKET ANALYSIS

Lupus Therapeutic Market, By Disease Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, and Neonatal Lupus), By Treatment Type (Non-Steroidal Anti-Inflammatory Drugs, Biologics, Antimalarial Drugs, Corticosteroids, and Others), By Route of Administration (Oral, Subcutaneous, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : May 2024
Code : CMI4958
Pages :167
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges: Side Effects of Drugs Used for Treatment of Lupus

The side effects of drugs used for the treatment of lupus is expected to hinder the growth of the global lupus therapeutic market over the forecast period. For instance, according to an article published by the Lupus Science and Medicine Journal (a peer-reviewed, open access journal) in March 2020, nearly all patients undergoing treatment for SLE report one or more adverse events such as nausea, vomiting, bone toxicity, and others.

Market Opportunities: Increasing Research and Development Activities

Increasing research and development activities among key market players is expected to offer lucrative growth opportunities over the forecast period. For instance, in November 2021, AstraZeneca, a U.K.-based biopharmaceutical company, announced positive results from its TULIP Phase 3 clinical trial program (focused on determining the efficacy and safety of Anifrolumab), stating that Saphnelo (anifrolumab) - a human monoclonal antibody showed greater reduction of SLE when used in combination with standard therapy than the use of only standard therapy.